
CLAIMS

That which is claimed:

1. A compound according to Formula I:



(I)

or a salt thereof wherein:

 indicates a single or double bond;

R^1 is $-CF_3$, $-C\equiv N$, or halo;

R^2 is H, C_{1-3} alkyl, or $-CHF_2$;

R^3 is C_{1-3} alkyl;

R^4 is $-C(CH_3)(CF_3)OH$, $-CH_2SCH_3$, $-CH_2S(O)_2CH_3$, $-C(O)CH_3$ or phenyl or pyridinyl, wherein said phenyl or pyridinyl is optionally substituted with one or two groups selected from $-C\equiv N$ and halo; and

R^5 is H or methyl.

2. A compound according to claim 1 wherein R^1 is $-CF_3$.

3. A compound according to claim 1 or 2 wherein R^2 is H.

4. A compound according to claim 1 or 2 wherein R^2 is methyl.


5. A compound according to any one of claims 1-4 wherein R^3 is methyl.

6. A compound according to any one of claims 1-5 wherein R^4 is $-CH_2S(O)_2CH_3$.

7. A compound according to any one of claims 1-6 wherein R^5 is H.

8. A compound according to any one of claims 1-6 wherein R^5 is methyl.

9. A compound or according to any one of claims 1-8, wherein said compound has formula I':



(I')

10. A compound according to claim 1, wherein said compound is selected from the group consisting of:

2-Methyl-1-(1-methyl-2-oxopropyl)-4-(trifluoromethyl)-1H-indole-5-carbonitrile;

1-(1-Ethyl-2-oxopropyl)-2-methyl-4-(trifluoromethyl)-1H-indole-5-carbonitrile;

2-Methyl-1-(1-(methylthio)propan-2-yl)-4-(trifluoromethyl)-1H-indole-5-carbonitrile;

2-Methyl-1-(1-(methylsulfonyl)propan-2-yl)-4-(trifluoromethyl)-1H-indole-5-carbonitrile;

2-Methyl-1-(1-(methylthio)butan-2-yl)-4-(trifluoromethyl)-1H-indole-5-carbonitrile;

2-Methyl-1-(1-(methylsulfonyl)butan-2-yl)-4-(trifluoromethyl)-1H-indole-5-carbonitrile;

1-(1-(Methylthio)propan-2-yl)-2-propyl-4-(trifluoromethyl)-1H-indole-5-carbonitrile;

2-(Difluoromethyl)-1-(1-(methylthio)propan-2-yl)-1H-indole-4,5-dicarbonitrile;

2-(Difluoromethyl)-1-(1-(methylsulfonyl)propan-2-yl)-1H-indole-4,5-dicarbonitrile;

1-(3-Oxobutan-2-yl)-4-(trifluoromethyl)-1H-indole-5-carbonitrile;

1-(1-(Methylthio)propan-2-yl)-4-(trifluoromethyl)-1H-indole-5-carbonitrile;

1-(1-(Methylsulfonyl)propan-2-yl)-4-(trifluoromethyl)-1H-indole-5-carbonitrile;


(R)-1-(1-(Methylsulfonyl)propan-2-yl)-4-(trifluoromethyl)indoline-5-carbonitrile;

1-(1-(Methylthio)butan-2-yl)-4-(trifluoromethyl)-1H-indole-5-carbonitrile;

1-(1-(Methylsulfonyl)butan-2-yl)-4-(trifluoromethyl)-1H-indole-5-carbonitrile;

4-Chloro-1-(3-oxobutan-2-yl)-1H-indole-5-carbonitrile;
(S)-4-Chloro-1-(1-(methylthio)propan-2-yl)-1H-indole-5-carbonitrile;
(S)-4-Chloro-1-(1-(methylsulfonyl)propan-2-yl)-1H-indole-5-carbonitrile;
(R)-4-Chloro-1-(1-(methylthio)propan-2-yl)-1H-indole-5-carbonitrile;
(R)-4-Chloro-1-(1-(methylsulfonyl)propan-2-yl)-1H-indole-5-carbonitrile;
(R)-1-(1-(Methylsulfonyl)propan-2-yl)-1H-indole-4,5-dicarbonitrile;
(R)-1-(1-(3-Cyanophenyl)ethyl)-4-(trifluoromethyl)-1H-indole-5-carbonitrile;
1-(1-(3-Cyanophenyl)propyl)-4-(trifluoromethyl)-1H-indole-5-carbonitrile;
(R)-1-(1-(5-Cyanopyridin-3-yl)propyl)-4-(trifluoromethyl)-1H-indole-5-carbonitrile;
(R)-4-Chloro-1-(1-(5-cyanopyridin-3-yl)propyl)-1H-indole-5-carbonitrile;
(*R*)-1-(1-Phenylethyl)-1H-indole-4,5-dicarbonitrile;
(*R*)-1-(1-(3-Cyanophenyl)ethyl)-1H-indole-4,5-dicarbonitrile;
4-Chloro-1-((2R,3S)-4,4,4-trifluoro-3-hydroxy-3-methylbutan-2-yl)-1H-indole-5-carbonitrile;
(S)-1-(1-(Methylthio)propan-2-yl)-4-(trifluoromethyl)-1H-indole-5-carbonitrile;
(S)-1-(1-(Methylsulfonyl)propan-2-yl)-4-(trifluoromethyl)-1H-indole-5-carbonitrile;
(*R*)-1-(1-(5-Cyanopyridin-3-yl)propyl)-1H-indole-4,5-dicarbonitrile;
1-((2R,3S)-4,4,4-Trifluoro-3-hydroxy-3-methylbutan-2-yl)-4-(trifluoromethyl)-1H-indole-5-carbonitrile;
and salts thereof.

11. The compound



12. A pharmaceutical composition comprising a compound according to any one of claims 1-11 and one or more pharmaceutically acceptable excipients.

13. A method of treating a disorder selected from muscle wasting associated with chronic obstructive pulmonary disease (COPD), muscle wasting associated with chronic

kidney disease (CKD), muscle wasting associated with chronic heart failure (CHF), and urinary incontinence, wherein said method comprises administering a compound according to any one of claims 1-11 to a human subject.

14. Use of a compound according to any one of claims 1-11 in the preparation of a medicament for the treatment of a disorder mediated selected from muscle wasting associated with chronic obstructive pulmonary disease (COPD), muscle wasting associated with chronic kidney disease (CKD), muscle wasting associated with chronic heart failure (CHF), and urinary incontinence,

15. A compound according to any one of claims 1-11 for use in the treatment of a disorder selected from muscle wasting associated with chronic obstructive pulmonary disease (COPD), muscle wasting associated with chronic kidney disease (CKD), muscle wasting associated with chronic heart failure (CHF), and urinary incontinence,


16. A method of accelerating hip fracture repair and healing, wherein said method comprises administering a compound according to any one of claims 1-11 to a human subject.

17. Use of a compound according to any one of claims 1-11 in the preparation of a medicament for the acceleration of hip fracture repair and healing.

18. A compound according to any one of claims 1-11 for use in the acceleration of hip fracture repair and healing.

CLAIMS

1. The compound



2. A pharmaceutical composition comprising a compound according to claim 1 and one or more pharmaceutically acceptable excipients.

3. Use of a compound according to claim 1 in the preparation of a medicament for the treatment of a disorder mediated selected from muscle wasting associated with chronic obstructive pulmonary disease (COPD), muscle wasting associated with chronic kidney disease (CKD), muscle wasting associated with chronic heart failure (CHF), and urinary incontinence.

4. A compound according to claim 1 for use in the treatment of a disorder selected from muscle wasting associated with chronic obstructive pulmonary disease (COPD), muscle wasting associated with chronic kidney disease (CKD), muscle wasting associated with chronic heart failure (CHF), and urinary incontinence.

5. Use of a compound according to claim 1 in the preparation of a medicament for the acceleration of hip fracture repair and healing.

6. A compound according to claim 1 for use in the acceleration of hip fracture repair and healing.

7. Use of a compound according to claim 1 in the preparation of a medicament for the acceleration of burn healing.

8. A compound according to claim 1 for use in the acceleration of burn healing.

9. The pharmaceutical composition according to claim 2, wherein said composition comprises 0.1-50 mgs of the compound.